PTC Therapeutics
| Company type | Public |
|---|---|
| Nasdaq: PTCT Russell 2000 Component | |
| Industry | Pharmaceuticals |
| Founded | 1 January 1998 |
| Headquarters | , United States |
| Website | ptcbio |
PTC Therapeutics is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.